Effect of Thiazolidinedione Amide on Insulin Resistance, Creactive Protein and Endothelial Function in Young Women with Polycystic Ovary Syndrome by Zhong, Wen-Yu et al.
Zhong et al 
Trop J Pharm Res, December 2015; 14(12): 2287  
 
Tropical Journal of Pharmaceutical Research December 2015; 14 (12): 2287-2292 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v14i12.19 
Original Research Article 
 
 
Effect of Thiazolidinedione Amide on Insulin Resistance, C-
reactive Protein and Endothelial Function in Young Women 
with Polycystic Ovary Syndrome 
 
Wen-Yu Zhong1,2, Hui Peng3,  Hua Li2, Hui Shang2, Yong-Qing Wei2, Zheng-Hui 
Fang2 and Xing-Bo Zhao1* 
1Department of Obstetrics & Gynecology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, 
250021, 2Department of Obstetrics & Gynecology, 3Department of Pediatrics, Jinan Central Hospital Affiliated to Shandong 
University, Jinan, Shandong, 250013, China 
 
*For correspondence: Email: zhaoxingbo458@gmail.com; Tel/Fax: 0086-531-87938911 
 
Received: 18 May 2015        Revised accepted: 31 October 2015 
 
Abstract 
Purpose: To investigate the effect of thiazolidinedione amide (TZDA) treatment on high-sensitivity C-
reactive protein (hsCRP) levels and endothelial dysfunction in patients with polycystic ovary syndrome 
(PCOS). 
Methods: Twenty five women (mean age 24.7 ± 3.9 years; mean body mass index (BMI), 23.2 ± 4.0 
kg/m2) with PCOS were treated with 15 µM TZDA daily for 12 months. Serum levels of testosterone, 
leutenizing hormone (LH), follicle stimulating hormone (FSH), sex hormone-binding globulin (SHBG), 
insulin and hsCRP were measured. BMI, hirsutism scores and insulin sensitivity indices were also 
calculated prior to and after TZDA treatment. Brachial artery responses to stimuli was used to measure 
arterial endothelium and smooth muscle function prior to and after the treatment. 
Results: TZDA treatment caused a significant (p < 0.05) decrease in serum testosterone from 93.1 ± 
40.3 to 54.8 ± 19.5 ng/dl and fasting insulin concentration from 11.9 ± 6.8 to 9.23 ± 5.13 U/mL. Insulin 
resistance index significantly (p < 0.05) improved and hirsutism score decreased significantly from 11.6 
± 2.0 to 6.8 ± 2.0. BMI, waist circumference, serum total cholesterol, low-density lipoprotein (LDL)-
cholesterol, FSH and LH levels remained almost unchanged. Twenty-four of the women reverted to 
regular menstrual cycles. SHBG levels showed a significant (p < 0.05) increase from 24.8 ± 9.5 to 49.1 
± 13.5 nmol/L after TZDA treatment. Serum hsCRP levels decreased (p < 0.05) from 0.25 ± 0.1 to 0.09 
± 0.02 mg/dL while endothelium-dependent vascular responses significantly improved (p < 0.05) 
following TZDA treatment (9.9 ± 3.9 vs 16.4 ± 5.1%). 
Conclusion: TZDA treatment improves insulin sensitivity, decreases androgen production and 
improves endothelial dysfunction in young women with PCOS. 
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Anovulation and hyper-androgenism are the 
characteristic features of polycystic ovary 
syndrome (PCOS). There are about 6 % of the 
women of reproductive age who suffer from 
PCOS [1]. The common features of the PCOS 
are resistance to insulin accompanied by 
simultaneous hyper-insulinemia [2,3]. The hyper-
insulinemia induces enhanced ovarian androgen 
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production and reduces serum sex hormone–
binding globulin concentration [4-6]. Inhibition of 
insulin secretion by diazoxide [7], metformin [8] 
or diet [9,10] in polycystic ovary syndrome 
patients leads to reduction in serum free 
testosterone concentrations. Insulin resistance in 
adolescent girls with hyperandrogenism clearly 
indicates involvement of hyper-insulinemia 
polycystic ovary syndrome [11]. 
 
It is reported that PCOS women exhibit 
significantly adverse coronary heart disease 
(CHD) risk profiles at relatively young age, 
suggesting that these increases may result in 
premature coronary atherosclerosis [12-15].Long 
incubation period in CHD associated with 
metabolic abnormalities observed in the teens or 
twenties among PCOS women might translate to 
measurable vascular abnormalities by middle 
age [14]. The atherosclerotic disease is 
characterised by the endothelial cell dysfunction 
which is an early event in the process of lesion 
formation [16-18]. Assessment of endothelial 
function by measuring flow-mediated dilatation 
(FMD) of the brachial artery is currently regarded 
as a potential tool for predicting CHD [19]. 
 
Dysfunction of the endothelium is associated with 
insulin resistance resulting in increased risk of 
atherosclerosis in insulin-resistant subjects, such 
as those with PCOS [20-22]. Atherosclerosis, a 
chronic inflammatory process and the measure 
of inflammatory markers like C-reactive protein 
(CRP) provide a method for assessment of 
cardiovascular risk [23]. Studies have 
demonstrated a correlation between insulin 
resistance and CRP concentrations [24-26]. 
Taking into consideration the concept that 
reducing insulin resistance may prevent early 
atherosclerosis, insulin sensitizers have been 
used in women with PCOS [26]. 
 
Troglitazone, amember of the thiazolidinedione 
(TZD) family, was found to have beneficial 
effects on insulin sensitivity and ovarian function 
in women with PCOS [27-29]. In a previous 
study, endothelial dysfunction in women with 
PCOS was improved by troglitazone therapy 
[30]. However, troglitazone was taken off the 
market as a result of concerns over its 
hepatotoxicity. The aim of our present study is to 
evaluate the efficiency of thiazolidinedione amide 
(TZDA) (Figure 1) therapy on insulin resistance, 
serum concentrations of pro-inflammatory 
markers and endothelial dysfunction in young 










The study was approved and performed 
according to the guidelines of the Ethics 
Committee for Human Studies of Shandong 
University, Jinan, Shandong, China and assigned 
it the reference number SU-023/2014. A written 
consent was obtained from all the patients after 
explanation of the nature, purpose and potential 




Twenty five women (mean age 24.7 ± 3.9 years) 
with PCOS were enrolled in our study. The 
selection of the patients was made on the basis 
of presence of two of the following three features: 
oligo- or anovulation; clinical Ferriman-Gallwey 
score>8 and/or biochemical signs of 
hyperandrogenism and polycystic ovaries. 
Biochemical criteria include abnormal luteinizing 
(LH):follicle-stimulating hormone (FSH) ratio (> 
2) and/or enhanced levels of testosterone. The 
PCO was diagnosed, on the basis ultrasound 
showing presence of 12 or more follicles per 
ovary 2-9 mm in diameter, and/or increased 
ovarian volume (> 10 ml). The mean cycle length 
in the patients was 52.7 ± 12.8 days and had 
normal thyroid, renal and hepatic functions. 
Women with pregnancy, use of oral 
contraceptives in 6 months period before the 
study, anti-androgens, anti-diabetics and known 
cardiovascular disease (CVD) were excluded 
from the study. For exclusion of Cushing’s 
syndrome and late-onset congenital adrenal 
hyperplasia dexamethazone suppression test 
and follicular phase serum 17-OH progesterone 
determination were done.  
 
Clinical examination and laboratory 
evaluation 
 
After 3 days of the treatment blood samples were 
collected, an oral glucose tolerance test and 
trans-vaginal ultrasonography were performed. 
Chemiluminescent enzyme immunoassay 
(Immulite 2000; Diagnostic Products Corporation, 
Los Angeles, CA, USA) was used to measure 
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serum concentrations of FSH, LH, testosterone, 
prolactin and sex hormone-binding globulin 
(SHBG). Glucokinase technique was used to 
measure serum glucose by the treatment of 
blood serum with glucokinase. The lipid profile 
measurement of the levels of total cholesterol, 
high- and low-density lipoprotein (HDL and LDL)-
cholesterol and triglyceride was also performed 
using commercial enzymatic methods (Aeroset 
automated analyzer, Abbott Diagnostics, IL, 
USA). Friedewald’s formula was used to 
calculate LDL-cholesterol. Chemiluminescent 
enzyme immunoassay (Immulite 1000 Analyser) 
and chemiluminescent enzyme immunoassay 
(Immulite 2000) were used for measuring plasma 
insulin levels and plasma hsCRP concentrations 
respectively. To determine insulin resistance 
various methods like fasting insulin, the 
homeostasis model assessment (HOMA) and the 
quantitative insulin sensitivity check index 
(QUICKI) were used. Insulin resistance was 
estimated using HOMA score.  
 
Arterial endothelium and smooth muscle 
functions were measured by examining brachial 
artery responses to endothelium-dependent and 
endothelium-independent stimuli employing 
ultrasonography. A 7.5 MHz transducer (Toshiba 
Power Vision 8000) was used to capture B-mode 
ultrasound images to determine brachial artery 
diameter. The scans were video-recorded later 
on analysis. We measured the arterial diameters 
during rest, during reactive hyperemia (FMD), 
again at rest and after treatment with 0.4 mg 
sublingual NTG. The end-diastolic arterial 
diameter was measured from one to the other 
media-adventitia interface and the 
measurements were made in triplicate at 
baseline, every 20 s after reactive hyperemia and 
after administration of NTG. All the women were 
treated with 15 µM TZDA per day. The patients 
were examined every month for 12 months and 
were admitted to the clinical research center. 
Clinical examinations and laboratory evaluations 
were performed, the results obtained were then 




Statistical analysis was performed using 
Statistical Package for Social Sciences (SPSS 
version 11.5) and the results are expressed as 
mean ± SD. Characteristics of distribution were 
tested using Kolmogorov–Smirn of test. 
Spearman’s rank correlation was used for these 
variables. Differences between means were 
analyzed using Student’s unpaired t-test and 




In our study all the 25 women enrolled completed 
the treatment without any report of adverse 
effects at the dosage of 15 µM TZDA per day for 
12 months. The results showed no enhancement 
in serum transaminases in all the tested patients 
during the TZDA treatment period. TZDA 
treatment for 12 months caused twenty-three 
patients to revert to the regular ovulatory cycles. 
The length of the cycles at the end of the 
treatment was 31.3 ± 4.5 days. All the clinical 
characteristics and hormonal parameters for the 
patients were recorded (Table 1). 
 
The results from our study revealed that TZDA 
treatment for 12 months induces only minor 
change in body weight without affecting waist 
circumferences. There was no significant change 
in total cholesterol, LDL, LH and FSH levels. 
TZDA treatment lead to a significant decrease in 
the hirsutism score from a baseline value of 11.6 
± 2.0 to 6.8 ± 2.0 after 12 months. Serum 
triglyceride concentrations were decreased and 
serum HDL concentrations were increased after 
treatment but these changes were statistically 
insignificant (p > 0.05). 
 
 
Table 1: Patient characteristics and hormone studies before and after TZDA treatment  
 
Variable Before TZDA (n = 25) Post-TZDA (n = 25) P-value 
BMI (kg/m2) 23.20 ± 4.00 27.10 ± 4.40 0.41 
Waist circumference (cm) 78.45 ± 7.54 82.35 ± 7.80 0.54 
Ferriman–Gallwey score 11.60 ± 2.10 8.30 ± 2.20 0.10 
LH (IU/l) 8.00 ± 5.60 8.30 ± 6.90 0.48 
FSH (IU/l) 3.98 ± 3.34 6.00 ± 3.10 0.49 
Testosterone (ng/dl) 93.10 ± 40.30 54.80 ± 19.50 0.03 
SHBG (nmol/l) 24.80 ± 9.50 49.10 ± 13.50 0.03 
Total cholesterol (mg/dl) 165.50 ± 40.40 159.90 ± 40.00 0.45 
Triglyceride (mg/dl) 125.00 ± 98.79 113.50 ± 69.60 0.12 
HDL-cholesterol (mg/dl) 45.70 ± 9.89 51.00 ± 10.78 0.10 
LDL-cholesterol (mg/dl) 93.25 ± 19.90 101.30 ± 30.80 0.28 
Values expressed as means ± S.E. 
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Serum testosterone levels decreased 
significantly after TZDA treatment from 93.1 ± 
40.3 to 54.8 ± 19.5 ng/dl whereas SHBG levels 
increased from 24.8 ± 9.5 to 49.1 ± 13.5 nmol/l. 
Serum hsCRP level also decreased significantly 
after 12 months of treatment from 0.25 ± 0.1 to 
0.09 ± 0.02 mg/dL (p < 0.05). 
 
Examination of the endothelium-dependent 
(FMD) vascular responses after TZDA treatment 
showed a significant improvement with an 
increase in value from 8.78 ± 4.8 to 17.2 ± 4.79 
% after 12 months (Figure 3). There was no 
change in baseline artery diameter and 
endothelium in-dependent vascular responses 




The endothelium releases different autocrine and 
paracrine substances which play vital roles in 
vascular homeostasis. In normal state 
endothelium suppresses pro-atherogenic 
processes, like monocyte and platelet adhesion, 
oxidation of LDLs, synthesis of inflammatory 
cytokines, smooth muscle proliferation and 
migration, and platelet aggregation. 
Atherosclerotic disease is characterized by onset 
of endothelial dysfunction [16,17]. For the 
detection of preclinical cardiovascular disease 
endothelial function is assessed using different 
methods like brachial artery ultrasound. 
Disorders like hypertension, 
hypercholesterolemia and insulin resistance are 
accompanied by reduced endothelium-
dependent vasodilatation [16]. It is reported that 
secondary hyperinsulinemia is the key factor 
responsible for the hyperandrogenism 
characteristic of PCOS, which is attributed to 
increased stimulation of the activity of the 
cytochrome P450c 17a in the ovary. 
 
There is a decrease in the concentration of 
circulating SHBG and increase in concentrations 
of free androgens in the blood in 
hyperinsulinemia [22]. 
 
Table 2: Glucose metabolism in patients before and after TZDA therapy (mean ± SEM, n = 25) 
 
Variable Before TZDA (n = 25) Post-TZDA (n = 25) P-value 
Fasting glucose (mg/dl) 89.61 ± 8.50 88.7 0± 8.78 0.31 
Fasting insulin (mU/ml) 11.90 ± 6.80 9.23 ± 5.13 0.02 
HOMA 3.21 ± 1.80 2.34 ± 0.67 0.02 
QUICKI 0.29 ± 0.03 0.41 ± 0.06 0.03 
 
 
Figure 3: Brachial artery responses in patients with PCOS after TZDA treatment. 
 
Table 3: Brachial artery responses, expressed as percentage dilatation from baseline (mean ± SEM, n = 25) 
 
Variable Before TZDA Post-TZDA  P-value 
Baseline artery diameter (BAD) (mm) 4.02 ± 0.38 4.04 ± 0.41 0.786 
FMD (%) 8.78 ± 4.80 17.20 ± 4.79 0.032 
NTG (%) 18.81 ± 4.91 22.30 ± 5.97 0.295 
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Both lean and obese women with PCOS have 
peripheral insulin resistance and 
hyperinsulinemia that appear to play a 
pathogenic role in the disease [22]. Previous 
studies have shown an endothelial dysfunction in 
women with PCOS [22]. Accumulating evidence 
also suggests that atherosclerosis represents a 
chronic inflammatory process and inflammatory 
markers like CRP provide an adjunctive method 
for global assessment of cardiovascular risk [22-
26]. Recent data also suggest that CRP may 
directly promote endothelial dysfunction by 
increasing the synthesis of soluble adhesion 
molecules, increasing monocyte chemo-
attractant protein secretion and facilitating 
macrophage LDL uptake [25]. In previous 
studies, high hsCRP levels and a link between 
insulin resistance and elevated CRP levels were 
shown in women with PCOS [22]. 
 
The use of insulin-sensitizing agents in the 
ovarian abnormalities of PCOS patients indicated 
the involvement of insulin. Such strategies also 
resulted in beneficial effects on the levels of 
markers for cardiovascular disease. Endothelial 
dysfunction and low-grade chronic inflammation 
being at the initial stages of atherosclerosis 
attracted us to investigate the effect of TZDA on 
hs CRP levels and endothelial dysfunction in 
women with PCOS.  
 
Rosiglitazone treatment was shown to improve 
ovulatory function and decrease insulin 
resistance in women with PCOS. The results 
from our study clearly demonstrated a significant 
decrease in insulin resistance and androgen 
levels along with improvement of ovulatory 
cycles in women with PCOS after TZDA 
treatment for 12 months. Earlier it was reported 
that rosiglitazone improves endothelial 
dysfunction and decrease hsCRP levels in non-
diabetic patients with coronary artery disease 
and also in non-diabetic patients with metabolic 
syndrome. The results from our study reveal that 
TZDA treatment improves endothelium-
dependent vasodilatation and decreases serum 
levels of pro-inflammatory marker hsCRP levels 
in PCOS patients. TZDA treatment also improved 
endothelial dysfunction and hsCRP levels in non-




Thus TZDA treatment improves insulin 
sensitivity, helps to restore ovulation and 
decrease androgen production in women with 
PCOS. Therefore, TZDA can be used for the 
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